Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 24 Issue 8, August 2025

GLP-1-based therapies p631.

Cover design: S. Harris

Volume 24 Issue 8

Subscribe

Comment

  • New approach methodologies (NAMs) have the potential to progressively transform medicines development by reducing reliance on animal testing while increasing the relevance of nonclinical data to patients. However, achieving regulatory acceptance of NAMs demands enhanced collaboration, clear guidance and continuous, science-based adaptation of the regulatory environment to accommodate emerging innovation.

    • Mariana Edwards
    • Oriane Blanquie
    • Falk Ehmann
    Comment

    Advertisement

Top of page ⤴

News & Analysis

Top of page ⤴

Research Highlights

Top of page ⤴

Reviews

  • An increasing array of biomarkers available in blood, cerebrospinal fluid and through imaging are providing valuable proxies of disease processes in neurodegenerative disorders (NDDs). In their Review, Cummings and co-authors discuss the implementation of biomarkers in clinical trials across various NDDs, focusing on the context of use, to help expedite and de-risk drug development.

    • Jeffrey L. Cummings
    • Charlotte E. Teunissen
    • Philip Scheltens
    Review Article

  • The aryl hydrocarbon receptor (AHR) mediates the toxic effects of environmental pollutants and regulates innate and adaptive immune responses. This Review discusses how, in the past, AHR activation was avoided during drug development, but now the AHR is being targeted for treating inflammation, cancer and infectious diseases.

    • Carolina M. Polonio
    • Kimberly A. McHale
    • Francisco J. Quintana
    Review Article

  • GLP-1-based therapies represent highly effective treatments for patients with type 2 diabetes and obesity. This Review profiles established and emerging GLP-1-based medicines, focusing on novel GLP-1 receptor agonists and GLP-1-based multi-agonists. Considerations and challenges in the development of GLP-1-based therapies and potential future indications are discussed.

    • Daniel J. Drucker
    Review Article
Top of page ⤴

Search

Advanced search

Quick links